CagriSema Lawsuit Advances, Adding Legal Overhang to Novo's Recovery Thesis

What happened

Novo Nordisk shareholders have sued the company, alleging it misled investors about the CagriSema clinical trial, and a U.S. judge has now allowed parts of that lawsuit to proceed. The litigation introduces a new dimension of legal risk to an investment case already grappling with intense oral GLP-1 competition from Eli Lilly and steep price erosion in the U.S. While the complaint's substance remains unproven, the mere advancement of the case threatens management credibility and could distract from the critical launch of oral Wegovy and the planned 2027 list-price reset. This development falls outside the risks previously detailed in our analysis and arrives at a moment when the stock is valued at a modest 11.8x P/E but with earnings still declining. Investors must now consider potential legal costs and reputational damage alongside the operational challenge of proving that volume growth can offset lower net prices.

Implication

Over the next 6-12 months, the CagriSema litigation adds a distraction and potential liability that could weigh on sentiment and management focus. While the financial impact is currently unquantifiable, it reinforces the need for caution and adds a new hurdle to Novo’s recovery narrative. Positive catalysts like oral Wegovy traction must now overcome not only competitive and pricing challenges but also this litigation overhang. Until the scope of the allegations and potential damages become clearer, the risk/reward tilts further toward a wait-and-see posture.

Thesis delta

The advancement of the CagriSema lawsuit adds a material, previously unaccounted-for legal risk to Novo’s investment thesis. This erodes some of the margin of safety and increases the burden of proof on operational stabilization to justify current valuation. We maintain a WAIT rating but adjust conviction lower given the new uncertainty, with a preference to see how the legal proceedings and Q2 results unfold before committing capital.